EANM 2022 – Barcelona, Spain
At the EANM congress held in Barcelona, Spain, and virtually from 15th – 19th October 2022, practice-changing data and high-quality education attracted more than 7,000 participants from over 121 countries. This memo inOncology special issue provides an insight into novel radio diagnostic tracers for PET imaging as well as biomarkers for prostate cancer. Moreover, patient reported outcomes, quality of life data and radioligand therapy for mCRPC with alpha emitters are summarized. The second part of this report deals with neuroendocrine tumor (NET) imaging updates including for example promising fluorine-18 labeled somatostatin analogues. As an add-on you can find data on the efficacy and safety of 177Lu-DOTATATE in pancreatic and midgut NETs as well as retrospective data of 225Ac-DOTATOC in the upfront as well as salvage treatment setting in patients with NETs.
Click here to learn more.
NANETS 2022 – Washington, USA
At the NANETS congress held in Washington, United States, and virtually from 27th – 29th October 2022, new therapeutic options were presented and the future of neuroendocrine tumor (NET) research discussed. The meeting made this year’s tagline “educating medical and professional researchers in the diagnosis and treatment of NET disease and supporting research and innovation in the field” more than just a slogan, thus, this memo inOncology report provides a comprehensive overview of three of the most actively investigated areas in the field: advances in peptide receptor radionuclide therapy, potential applications of “passive” and “active” immunotherapy and novel biomarkers.
Click here to learn more.